Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
$3.41
$3.51
$3.96
$12.00
$6.11M1.557,305 shs284 shs
Equillium, Inc. stock logo
EQ
Equillium
$0.33
+2.7%
$0.37
$0.27
$1.50
$11.68M1.86439,726 shs40,195 shs
Graphite One Inc. stock logo
GPH
Graphite One
C$0.67
-1.5%
C$0.79
C$0.64
C$1.07
C$67.84M1.0272,369 shs18,610 shs
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
$0.29
$0.15
$0.84
$10.93M1.3160,047 shs1.27 million shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.00%+2.10%-8.33%+33.18%-28.21%
Equillium, Inc. stock logo
EQ
Equillium
0.00%+5.48%-13.95%-27.53%-51.90%
Graphite One Inc. stock logo
GPH
Graphite One
0.00%-2.90%-23.86%-23.86%-1.47%
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/AN/AN/AN/AN/AN/AN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
1.8 of 5 stars
3.22.00.00.01.11.70.6
Graphite One Inc. stock logo
GPH
Graphite One
N/AN/AN/AN/AN/AN/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.00
N/AN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
2.33
Hold$3.00817.43% Upside
Graphite One Inc. stock logo
GPH
Graphite One
0.00
N/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
3.00
Buy$2.50∞ Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
$2.37M2.58N/AN/A$14.99 per share0.23
Equillium, Inc. stock logo
EQ
Equillium
$41.10M0.28N/AN/A$0.54 per share0.61
Graphite One Inc. stock logo
GPH
Graphite One
N/AN/AC$0.01 per share94.17C$0.44 per shareN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/A$0.32 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
-$16.55M-$14.86N/AN/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)
Equillium, Inc. stock logo
EQ
Equillium
-$8.07M-$0.39N/AN/AN/A-19.62%-74.34%-46.75%8/6/2025 (Estimated)
Graphite One Inc. stock logo
GPH
Graphite One
-C$4.90M-C$0.07N/AN/AN/A-10.96%-6.61%N/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/AN/AN/AN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/AN/AN/A
Graphite One Inc. stock logo
GPH
Graphite One
N/AN/AN/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/A
5.94
5.93
Equillium, Inc. stock logo
EQ
Equillium
N/A
2.70
2.70
Graphite One Inc. stock logo
GPH
Graphite One
0.02
1.09
0.33
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/A
9.57
9.57

Institutional Ownership

CompanyInstitutional Ownership
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.73%
Equillium, Inc. stock logo
EQ
Equillium
27.05%
Graphite One Inc. stock logo
GPH
Graphite One
0.07%
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
12.38%

Insider Ownership

CompanyInsider Ownership
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.10%
Equillium, Inc. stock logo
EQ
Equillium
30.30%
Graphite One Inc. stock logo
GPH
Graphite One
28.81%
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
33.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
201.79 million1.79 millionNo Data
Equillium, Inc. stock logo
EQ
Equillium
4035.72 million24.90 millionNot Optionable
Graphite One Inc. stock logo
GPH
Graphite One
20101.25 millionN/ANot Optionable
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
1669.64 million46.59 millionNot Optionable

Recent News About These Companies

Medicenna’s MDNA11 Shows Promise in Cancer Treatment
Medicenna Showcases Promising Results and Strong Financials
Medicenna to Present Innovative Cancer Data at Conferences
Medicenna Announces Breakthroughs in Cancer Treatment
3 TSX Growth Stocks To Watch With Up To 39% Insider Ownership

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aeterna Zentaris stock logo

Aeterna Zentaris NASDAQ:AEZS

$3.41 0.00 (0.00%)
As of 07/3/2025

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Equillium stock logo

Equillium NASDAQ:EQ

$0.33 +0.01 (+2.67%)
Closing price 07/3/2025 03:20 PM Eastern
Extended Trading
$0.33 0.00 (0.00%)
As of 07/3/2025 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Graphite One stock logo

Graphite One CVE:GPH

C$0.67 -0.01 (-1.47%)
As of 07/4/2025 03:23 PM Eastern

Graphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Medicenna Therapeutics stock logo

Medicenna Therapeutics NASDAQ:MDNA

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.